Argomenti trattati
Across more than forty years in the life sciences, Rick E Winningham has combined commercial leadership with a deliberate focus on developing talent. Today he is being recognized as the 2026 HBA Honorable Mentor by the Healthcare Businesswomen’s Association, an honor reserved for a single executive who uses influence to expand opportunity, promote representation, and cultivate leaders at all stages. This recognition reflects a career-long pattern of elevating colleagues, shaping organizational culture, and advocating for programs that prepare diverse candidates for senior roles.
Winningham’s approach to leadership treats mentorship and sponsorship as strategic priorities rather than optional activities. He describes these activities as practical investments in teams that lead to stronger decisions and better outcomes for patients. In addition to his corporate responsibilities, his board service and external advocacy extend the reach of that philosophy across the broader biopharmaceutical ecosystem.
A career rooted in scientific innovation and executive leadership
Rick E Winningham currently serves as CEO and Director of Theravance Biopharma, a role he has held since the company’s separation from Innoviva in June 2014. He joined the company’s board in July 2013 and served as Chairman until October 2026. Earlier in his career, Winningham held senior leadership roles at Bristol Myers Squibb, including responsibilities as President of Oncology and Immunology. Over four decades in industry, he has overseen programs that brought scientific concepts to market while mentoring the next generation of executives and scientists.
Tangible impact at Theravance and across industry boards
Under his leadership at Theravance, Winningham has emphasized equitable opportunity and visible advancement. Today, more than half of Theravance’s senior leadership team are women — a measurable outcome of long-term attention to talent development and organizational design. Beyond Theravance, he has contributed to governance and strategy through board engagements with the Biotechnology Innovation Organization, the California Healthcare Institute, and California Life Sciences (CLS), using those platforms to advocate for processes that broaden access to leadership roles around the world.
Mentorship in practice
Winningham frames mentorship as hands-on guidance and sponsorship as active advocacy that opens doors for rising talent. He has encouraged peers and direct reports to pursue formal development opportunities such as the Boardroom Ready program and has personally mentored dozens of members of the Healthcare Businesswomen’s Association. His actions — promoting qualified candidates, recommending individuals for board roles, and creating internal pathways — illustrate how sustained support converts potential into leadership.
Board-level influence and industry advocacy
At the governance level, Winningham’s role is not only strategic but also cultural: he has used board seats to press for diversity in leadership pipelines and to influence hiring and succession planning across institutions. His advocacy extends beyond singular appointments to systemic changes that encourage transparency, talent mobility, and inclusive decision-making processes that enhance innovation and organizational resilience.
Recognition and the road ahead
The HBA Honorable Mentor award recognizes executives who make mentorship central to their leadership. Winningham says this recognition underlines his belief that creating environments where people can grow and be visible is essential to transforming patient care. He will be honored and deliver a keynote address at the 2026 HBA Global Ascension Leadership Awards Experience, scheduled for 23–24 April 2026 in San Diego, California, where industry leaders will gather to discuss strategies that navigate complexity in healthcare and life sciences.
Legacy and continued commitment
For Rick E Winningham, the honor is both a milestone and a mandate: to continue building pathways that enable talented leaders to contribute fully to science and patient care. His consistent emphasis on leadership development, formal programs, and active mentorship aims to ensure that future executives are prepared to tackle the evolving challenges of the biopharmaceutical sector.